Collaborations

Collaborations ESTEVE

R&D has been present in ESTEVE's DNA since our inception. Partnerships with Centers of Excellence give us access to knowledge, talent and cutting-edge technologies in our field and integrate us into an open ecosystem of innovation.


The purpose is to access highly innovative projects that offer a real added value to patients.

Our goal


Is to develop innovative R&D partnership models with companies and academic centers in order to accelerate the transfer of science to a possible new drug.


A good example of the company's commitment to research being its raison d'être, is the location of ESTEVE's Preclinical Discovery and Development Center facilities in the Parc Científic de Barcelona (PCB), one of the leading European ecosystems for research, technological transfer and innovation in life sciences.


Our wide range of R&D collaborations includes Joint Strategic Units, Strategic Collaborations and Research Consortia. We highlight the following in particular:

Parc Científic de Barcelona
Joint Strategic Units

Joint Strategic Units


- Chemical Research Institute of Catalonia (ICIQ), Tarragona: Joint ESTEVE-ICIQ Unit


- University of Santiago de Compostela (USC): Joint ESTEVE-USC Unit


- Barcelona Science Park (PCB): Joint ESTEVE-PCB Unit


- Pompeu Fabra University (UPF): Joint ESTEVE-UPF Unit

Strategic partnerships


- University of Granada


- Prince Felipe Research Center, Valencia


- Cajal Institute, CSIC, Madrid


- King Juan Carlos University, Alcorcón


- Autonomous University of Barcelona (UAB): ESTEVE-UAB Public-Private partnership in gene therapy


- Companies: Enantia, Galchimia, Neural Therapies, Brammer Bio, and others.


Strategic partnerships

Research Consortia


ESTEVE's participation in public-private consortiums for pre-competitive projects is described below. There is also information about R&D projects that have received public grants.

 

Objective: Generation of new models for neuropathic pain with a high predictive value for the preclinical assessment of new treatments and the identification of biomarkers of interindividual variability and the effectiveness of the treatment on patients.



The NeuroPain project has received funding from the European Union's Seventh Framework Programme (#HEALTH-F2-2013-602891).

Objective: Generation of in vitro translational models to predict the therapeutic profile of new drugs on pain.


Phenopain has received funding from the RETOS-COLABORACIÓN program of Spain's Ministry of Economy and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (ERDF).

Objective: Development of innovative chemical processes in continuous flow for the preparation of useful new pharmaceutical active ingredients for the chemical-pharmaceutical industry.


FLOW4HEALTH has received funding from the RETOS-COLABORACIÓN program of Spain's Ministry of Economy and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (ERDF).

Objective: to promote programs in the field of rare diseases, via a network of collaboration between highly innovative enterprises and prestigious hospital research centers in Catalonia. ESTEVE's participation centres around validating and correlating biomarkers of specific monogenic diseases.


The project, awarded by the regional Catalan government's Agency for Corporate Competitiveness (ACCIÓ), has been financed by the European Union through the European Regional Development Fund (ERDF).

Objective: Discovery of new therapeutic approaches for the treatment of chronic pain, trough of the preclinical validation of new pharmacological targets and innovative mechanism of action involved in the neuroinflammatory process with an impact for the treatment of chronic pain.


Inflapain has received funding from the RETOS-COLABORACIÓN program of Spain's Ministry of Science, Innovation and Universities and has been co-financed by the European Union through the European Regional Development Fund (ERDF).

Objective: preclinical pharmacological identification and validation of molecular targets differentially expressed in specific cell populations under neuropathic pain conditions, with potential impact for pain relief and to avoid its progression and chronification.


Ribopain has received funding from the RETOS-COLABORACIÓN program of Spain's Ministry of Science, Innovation and Universities and has been co-financed by the European Union through the European Regional Development Fund (ERDF).

Objective: to use clinically relevant models to identify the most prevalent mechanisms for disease in the interactions that take place between neurons and glia. The knowledge acquired will allow the identification of therapeutic targets and biomarkers, as well the creation of new screening systems to identify new analgesics for the treatment of neuropathic pain.


The NGN-PET project is funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking.

Objective: to improve the care of patients suffering from acute or chronic pain trough the alignment on responses in postoperative acute pain and in chronic pain in the clinical practice; the refinement of preclinical pain models and improvement of their translation identification of biomarkers and providing new approaches for patient stratification in clinical trials.


The PainCare project is funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking.

The internal projects developed in collaboration with multiple centres were financed mainly with Esteve's own resources, to which some competitive public grants has been added. Esteve has neither requested nor has it ever received funding from patients' associations or private individuals.


E-52862 has received grants from the Spains's Ministry of Economy and Competitiveness, via the Centre for Industrial Technological Development (CDTI) for clinical validation in neuropathic pain, as well as the projects Multimodal-1, Multimodal-2, Multimodal-3, Multimodal-5 and Sigma-1 new indications, that have also been partially co-financed by the European Union via the European Regional Development Fund (ERDF).


Project E-58425 has received a grant by the Catalonia Trade & Investment Agency (ACC1Ó) of the Generalitat de Catalunya as part of the line of loans for industrial innovation and experimental development projects via the Catalan Institute of Finance (ICF).


The Sanfilippo project has received grants from the Spain's Ministry of Economy and Competitiveness and the Ministry of Health, Social Policy and Equality, in competitive calls for research projects, in which the project was recognized for its scientific excellence.